Having controversially approved the first new Alzheimer’s disease drug Aduhelm (aducanumab) in decades in 2021, dead on schedule, the US Food and Drug Administration on Friday announced its decision on a follow-on product. And it was positive.
The FDA granted accelerated approval for Japanese drugmaker Eisai (TYO: 4523) and US biotech company Biogen’s (Nasdaq: BIIB) Leqembi (lecanemab-irmb) for the treatment of Alzheimer’s. Biogen shares, trading of which had been suspended ahead of the announcement, moved up 4.4% to $282.06. The news came long after Tokyo trading closed.
The approved labelling is much as expected, and encourages treatment initiation only in patients with mild cognitive impairment or mild dementia (similar to enrollment criteria in the trial). The label included warnings and precautions related to amyloid-related imaging abnormalities (ARIA) during the first 14 weeks of treatment, with an increased risk of ARIA in APOE4 homozygotes compared to heterozygotes and noncarriers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze